Multidrug-resistant gram-negative pathogens: Multiple approaches and measures for prevention

Infection Control and Hospital Epidemiology

Volumn 27, Issue 9, 2006, Pages 889-892

  Patterson, Jan E ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; IMIPENEM; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; EDITORIAL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; MORTALITY; MULTIDRUG RESISTANCE; TREATMENT FAILURE;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; HOSPITAL MORTALITY; HUMANS; RISK FACTORS;

EID: 33749021970     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/507436     Document Type: Editorial

References (23)

1. Gardiner DF, Scholand SJ, Babinchak. Mortality and gram-negative rod bacteremia in the intensive care unit. J Hosp Infect 2006; 62:453-457.
2. Friedman G, Sliva E, Vincent JL. Has the mortality of septic shock changed with time? Crit Care Med 1998; 26:2078-2080.
3. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006; 27:893-900 (in this issue).
4. Fortaleza CMCB, Freire MP, Moreira Filho DC, Carvalho Ramos M. Risk factors for recovery of imipenem- or ceftazidime-resistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect Control Hosp Epidemiol 2006; 27:901-906 (in this issue).
5. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001; 32:1055-1061.
6. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: addressing the limitation of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005; 26:346-351.
7. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002; 34:340-345.
8. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25:1094-1098.
9. Gales AC, Menezes LC, Silbert S, Sader HS. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. J Antimicrob Chemother 2003; 52:699-702.
10. Aubert G, Pozzetto B, Dorche G. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy. J Antimicrob Chemother 1992; 29:307-312.
11. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474.
12. Marra AR, Pereira CAP, Gales AC, et al. Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes. Antimicrob Agents Chemother 2006; 50:388-390.
13. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49:760-766.
14. Gomes CC, Vormittag E, Santos CR, Levin AS. Nosocomial infection with cephalosporin-resistant Klebsiella pneumoniae is not associated with increased mortality. Infect Control Hosp Epidemiol 2006; 27:907-912 (in this issue).
15. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155.
16. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. Arch Intern Med 2005; 165:1375-1380.
17. Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 2006; 42(Suppl 4):S164-S172.
18. Harbarth S, Garbino I, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529-535.
19. Bates DW, Pruess KE, Lee TH. How bad are bacteremia and sepsis? Outcomes in a cohort with suspected bacteremia. Arch Intern Med 1995; 155:593-598.
20. Dupont H, Montravers P, Gauzit R, et al. Outcome of postoperative pneumonia in the EOLE study. Intensive Care Med 2003; 29:179-188.
21. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206-2212.
22. Andes D, Craig WA. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 2005; 11(Suppl 6):10-17.
23. Gunale A, von Baum P, Wendt C. Survival of cephalosporin-resistant Enterobacteriaceae on fingers. Infect Control Hosp Epidemiol 2006; 27:974-977 (in this issue).